BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback